BRIEF—Launch plans for Symjepi in the USA

Sandoz Inc, a US division of Swiss pharma giant Novartis, plans to launch Symjepi (epinephrine) 0.3mg Injection in the USA in early first-quarter 2019 for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.

The US Food and Drug Administration granted approval in August for Symjepi, for which  Sandoz acquired exclusive US distribution rights from Adamis Pharmaceuticals in July.

“We are actively preparing for the US market introduction of Symjepi, and with manufacturing completed, we are well underway to ensure appropriate supply of this life-saving medicine for healthcare professionals and patients in need of a new treatment option,” said Sandoz.

Sandoz’ planned wholesale acquisition cost (WAC) for a two-pack of Symjepi 0.3mg Injection is $250, which is about 16.5% less than the WAC of Mylan’s authorized generic EpiPen and Teva’s generic EpiPen.